[Results of the "Ocular hypertension treatment study"]
- PMID: 15702319
- DOI: 10.1007/s00347-004-1150-x
[Results of the "Ocular hypertension treatment study"]
Abstract
Ocular hypertension (OHT) is defined as intraocular pressure (IOP) elevated above normal levels which occurs without detectable damage to the papilla or visual field. It is considered to be the most important risk factor for developing primary open-angle glaucoma (POAG). The "Ocular hypertension treatment study" (OHTS) addresses the issue of whether lowering IOC before damage to the papilla or visual field occurs can hinder their development and whether OHT can be treated categorically. This randomized, prospective, nonmasked and non-placebo-controlled, multicenter study documents the protective effect of prophylactic lowering of IOC and identifies and explains the risk factors for developing POAG. These include advancing age, reduced corneal thickness, increased pattern standard deviations in white-on-white perimetry, and elevated vertical or horizontal cup to disc ratio. Due to the large individual differences in risk distribution and the very high costs of treating OHT, the question of whether OHT should be treated on principle remains open in the OHTS. This decision must be made on an individual basis after each patient's risk has been assessed.
Similar articles
-
The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30. doi: 10.1001/archopht.120.6.714. Arch Ophthalmol. 2002. PMID: 12049575 Clinical Trial.
-
[Glaucoma and ocular hypertension: the importance of intraocular pressure in treatment decisions in France].J Fr Ophtalmol. 2003 Nov;26(9):895-903. J Fr Ophtalmol. 2003. PMID: 14631273 French.
-
The Ocular Hypertension Treatment Study: design and baseline description of the participants.Arch Ophthalmol. 1999 May;117(5):573-83. doi: 10.1001/archopht.117.5.573. Arch Ophthalmol. 1999. PMID: 10326953 Clinical Trial.
-
Ocular Hypertension Treatment Study (OHTS) commentary.Curr Opin Ophthalmol. 2003 Apr;14(2):74-7. doi: 10.1097/00055735-200304000-00003. Curr Opin Ophthalmol. 2003. PMID: 12698045 Review.
-
Treatment choices for newly diagnosed primary open angle and ocular hypertension patients.Eye (Lond). 2020 Jan;34(1):60-71. doi: 10.1038/s41433-019-0633-6. Epub 2019 Nov 4. Eye (Lond). 2020. PMID: 31685971 Free PMC article. Review.
Cited by
-
Glaucoma: recent advances in the involvement of autoimmunity.Immunol Res. 2017 Feb;65(1):207-217. doi: 10.1007/s12026-016-8837-3. Immunol Res. 2017. PMID: 27475096 Review.
-
Intraocular pressure measurement with Corvis ST in comparison with applanation tonometry and Tomey non-contact tonometry.Int Ophthalmol. 2019 Nov;39(11):2517-2521. doi: 10.1007/s10792-019-01098-5. Epub 2019 Apr 9. Int Ophthalmol. 2019. PMID: 30968328
-
Serum and antibodies of glaucoma patients lead to changes in the proteome, especially cell regulatory proteins, in retinal cells.PLoS One. 2012;7(10):e46910. doi: 10.1371/journal.pone.0046910. Epub 2012 Oct 11. PLoS One. 2012. PMID: 23071659 Free PMC article.
-
Autoantibody Biomarker Discovery in Primary Open Angle Glaucoma Using Serological Proteome Analysis (SERPA).Front Immunol. 2019 Mar 7;10:381. doi: 10.3389/fimmu.2019.00381. eCollection 2019. Front Immunol. 2019. PMID: 30899261 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical